STOCK TITAN
  1. Home
  2. Sec-filings
  3. IOVA
  4. [Form 4] IOVANCE BIOTHERAPEUTICS, INC. Insider Trading Activity

IOVANCE (IOVA) CMO reports RSU vesting and tax withholding share disposition

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported routine equity compensation activity involving restricted stock units (RSUs) and related tax withholding. On the transaction date, RSUs covering 8,790 shares of common stock vested, and an equivalent number of common shares were issued upon conversion of the RSUs.

To cover mandatory tax withholding on this vesting, 4,473 common shares were withheld by the company at a price of $3.96 per share, which the filing notes was not an open market sale. After these transactions, the reporting person directly held 136,274 shares of common stock and 26,369 RSUs, with the remaining RSUs scheduled to vest in equal quarterly installments.

Positive

  • None.

Negative

  • None.
Insider GRAF FINCKENSTEIN FRIEDRICH
Role Chief Medical Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 8,790 $0.00 --
Exercise Common Stock 8,790 $0.00 --
Tax Withholding Common Stock 4,473 $3.96 $18K
Holdings After Transaction: Restricted Stock Units — 26,369 shares (Direct, null); Common Stock — 140,747 shares (Direct, null)
Footnotes (1)
  1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. Represents the common stock remaining after deducting the common stock withheld for taxes. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The remaining RSUs will vest in equal quarterly installments. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
RSUs vested 8,790 shares Restricted stock units converting into common stock on transaction date
Shares withheld for taxes 4,473 shares Common stock withheld to satisfy mandatory tax withholding
Withholding reference price $3.96 per share Price used for tax withholding share value
Common stock held after 136,274 shares Direct common stock ownership following transactions
RSUs remaining 26,369 units Remaining RSUs after vesting event, vesting quarterly
Restricted Stock Units financial
"Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
mandatory tax withholding financial
"Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs."
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
contingent right financial
"Each RSU represents a contingent right to receive one share of the Issuer's common stock."
vest in equal quarterly installments financial
"The remaining RSUs will vest in equal quarterly installments."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GRAF FINCKENSTEIN FRIEDRICH
(Last)(First)(Middle)
C/O IOVANCE BIOTHERAPEUTICS, INC.
825 INDUSTRIAL ROAD, SUITE 100
(Street)
SAN CARLOS CALIFORNIA 94070
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock(1)06/01/2026M8,790A$0140,747D
Common Stock(2)06/01/2026F4,473D$3.96136,274(3)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(4)06/01/2026M8,790 (5) (5)Common stock8,790$0.0026,369(6)D
Explanation of Responses:
1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
3. Represents the common stock remaining after deducting the common stock withheld for taxes.
4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
5. The remaining RSUs will vest in equal quarterly installments.
6. Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person.
/s/ Friedrich Graf Finckenstein06/03/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What equity transactions did IOVANCE BIOTHERAPEUTICS (IOVA) report for its Chief Medical Officer?

The Chief Medical Officer reported RSUs for 8,790 shares vesting into common stock. To satisfy tax obligations, 4,473 shares were withheld by the company. The filing characterizes this as routine compensation-related activity rather than an open market share sale.

Did the IOVA Chief Medical Officer sell shares in the open market in this Form 4?

No, the filing states the 4,473 shares were withheld to meet mandatory tax withholding upon RSU vesting. It explicitly notes this withholding is not an open market sale, distinguishing it from discretionary buying or selling on a stock exchange.

How many IOVA shares does the Chief Medical Officer hold after these transactions?

Following the RSU vesting and tax withholding, the Chief Medical Officer directly holds 136,274 shares of IOVANCE common stock. In addition, 26,369 RSUs remain outstanding, which represent future contingent rights to receive additional shares as they vest over time.

What happened to the restricted stock units (RSUs) reported in this IOVA Form 4?

RSUs covering 8,790 shares of common stock vested and converted into the same number of common shares. Each RSU represents a contingent right to receive one share, and the remaining RSUs will vest in equal quarterly installments according to the disclosed vesting schedule.

Are the remaining RSUs for the IOVA Chief Medical Officer subject to a vesting schedule?

Yes, the filing notes that the remaining RSUs will vest in equal quarterly installments. The aggregate 26,369 RSUs reflect the remainder of a grant made on March 1, 2024, and do not include any other RSUs the reporting person may hold.